IP Library Granted Patent US 8,247,437
Granted Patent B2
US 8,247,437 · App. 13/155,411 · Granted Aug 21, 2012

N-hydroxyamide derivatives and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,247,437
App. No.
13/155,411
Granted
Aug 21, 2012
Kind
B2
Abstract

The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.

Claims (55)

1. A N-hydroxyamide according to Formula (I),

wherein:

A is —C(B)—;

B is B forms a bond with either R 5 or R 7 ;

R 1 is selected from C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, benzofuranyl, amino and alkoxy;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 -cycloalkyl, and aryl;

R 3 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl;

R 4 , R 5 , R 6 and R 7 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl; or R 4 and R 7 form together a —CH 2 — linkage;

n is an integer selected from 1, 2, 3, 4, 5 and 6;

wherein R 1 -R 7 may be substituted by from 1 to 5 substituents selected from the group consisting of C 1 -C 6 -alkyl, amino, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, and nitro;

Carbons (2) and (3) are two chiral centers, wherein chiral center (2) has a configuration selected from “S” and “R” and wherein chiral center (3) has a “S” configuration as well as pharmaceutically acceptable salts thereof.

2. A N-hydroxyamide according to claim 1 , wherein R 1 is selected from aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, and benzofuranyl.

3. A N-hydroxyamide according to claim 1 wherein R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl.

4. A N-hydroxyamide according to claim 1 wherein R 2 is aryl.

5. A N-hydroxyamide according to claim 1 wherein R 2 is selected from optionally substituted C 3 -C 8 -cycloalkyl.

6. A N-hydroxyamide according to claim 1 wherein R 3 is H.

7. A N-hydroxyamide according to claim 1 wherein R 4 , R 5 and R 7 are H.

8. A N-hydroxyamide according to claim 1 wherein R 6 is selected from H and C 1 -C 6 alkyl.

9. A N-hydroxyamide according to claim 1 wherein R 5 and R 6 are H and R 4 and R 7 can form together a —CH 2 — linkage.

10. A N-hydroxyamide according to claim 1 wherein the configuration of the chiral carbons is (2S), (3S).

11. A N-hydroxyamide according to claim 1 wherein the configuration of the chiral carbons is (2R), (3S).

12. A N-hydroxyamide according to claim 1 having a Formula (Ib):

wherein A is a carbon atom;

R 1 is selected from H, C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, benzofuranyl, amino and alkoxy;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 -cycloalkyl, and aryl;

R 3 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl;

R 4 , R 6 and R 7 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl; or R 4 and R 7 form together a —CH 2 — linkage;

n is an integer selected from 1, 2, 3, 4, 5 and 6;

Carbons (2) and (3) are two chiral centers, wherein chiral center (2) has a configuration selected from “S” and “R” and wherein chiral center (3) has a “S” configuration as well as pharmaceutically acceptable salts thereof.

13. A N-hydroxyamide according to claim 12 wherein R 1 is selected from aryl and R 3 , R 4 , R 5 , R 6 and R 7 are H.

14. A pharmaceutical composition comprising at least one N-hydroxyamide according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient thereof.

15. A process for the preparation of a N-hydroxyamide according to claim 1 , comprising reacting a compound of Formula (IV) with H 2 N—O—R 8 :

wherein A, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 and n are as defined in claim 1 and R 8 is selected from H and a protective group selected from t-butyl, benzyl, trialkylsilyl, tetrahydropyranyl.

16. A process for the preparation of a N-hydroxyamide according to claim 1 , comprising reacting a compound of Formula (V) with H 2 N—O—R 8 :

wherein A, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 and n are as defined in claim 1 and R 8 is selected from H and a protective group.

17. A process according to claim 15 , further comprising removing the protecting group of R 8 when R 8 is a protective group.

18. A process for the preparation of a N-hydroxyamide according to claim 15 , further comprising reacting a compound of Formula (II) with an amine of Formula (III) to form the intermediate of Formula (IV), optionally in presence of a coupling agent selected from DIC, EDC, TBTU, DCC, HATU, PyBOP®, Isobutyl chloroformate and 1-methyl-2-chloropyridinium iodide

wherein A, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 and n are as defined in claim 15 ; G is a group selected from OH and Cl.

19. A compound according to Formula (IV):

wherein A is —C(B)—;

B forms a bond with either R 5 or R 7 ;

R 1 is selected from C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, benzofuranyl, amino and alkoxy;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 -cycloalkyl, and aryl;

R 4 , R 5 , R 6 and Rare independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl; or R 4 and R 7 form together a —CH 2 — linkage;

n is an integer selected from 1, 2, 3, 4, 5 and 6;

wherein R 2 , R 4 , R 5 , R 6 and R 7 may be substituted by from 1 to 5 substituents selected from the group consisting of C 1 -C 6 -alkyl, amino, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, and nitro.

20. A compound according to Formula (V):

wherein

A is —C(B)—;

B forms a bond with either R 5 or R 7 ;

R 1 is selected from C 1 -C 6 alkyl, C 3 -C 8 -cycloalkyl, aryl, pyridinyl, pyrazinyl, thiadiazolyl, pyrimidinyl, oxadiazolyl, quinolinyl, thienyl, benzofuranyl, amino and alkoxy;

R 2 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 -cycloalkyl, and aryl;

R 4 , R 5 , R 6 and R 7 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl; or R 4 and R 7 form together a —CH 2 — linkage;

n is an integer selected from 1, 2, 3, 4, 5 and 6;

wherein R 2 , R 4 , R 5 , R 6 and R 7 may be substituted by from 1 to 5 substituents selected from the group consisting of C 1 -C 6 -alkyl, amino, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, and nitro.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2017
From: MERCK SERONO S.A.
To: MERCK PATENT GMBH
Reel/Frame 043839/0219 →